Related Experiment Video
Updated: Jul 7, 2025
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
Mortality benefit with AF ablation: Impact of normal sinus rhythm seen in CABANA and EAST AFnet
Michael Crawford1, Benjamin A Steinberg1, Ravi Ranjan1
1Department of Internal Medicine, Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Insights
Early rhythm control therapy for atrial fibrillation (AF) significantly reduces mortality and morbidity. Recent trials show catheter ablation and early intervention improve outcomes, offering new hope for managing AF risks.
Area of Science:
- Cardiology
- Clinical Trials
- Atrial Fibrillation Management
Background:
- Atrial fibrillation (AF) significantly increases morbidity and mortality.
- Standard care involves oral anticoagulation for stroke risk, but rate vs. rhythm control remains debated.
- Historical trials showed no significant outcome difference between rate and rhythm control.
Purpose of the Study:
- To evaluate contemporary data on rhythm control strategies for atrial fibrillation.
- To assess the impact of early rhythm control and catheter ablation on AF outcomes.
- To determine if improved therapeutic interventions can mitigate AF-related mortality risks.
Main Methods:
- Analysis of recent clinical trials including EAST-AFNET and CABANA.
- Comparison of rhythm control strategies versus rate control in AF patients.
- Evaluation of catheter ablation efficacy against medical therapy for AF.
Main Results:
- The EAST-AFNET trial demonstrated a significant mortality and morbidity advantage for early rhythm control with comprehensive management.
- The CABANA trial showed catheter ablation to be more effective long-term than medical therapy for AF.
- Effective rhythm control, irrespective of therapy, was associated with lower adverse outcomes and mortality.
Conclusions:
- Contemporary data suggest early rhythm control, particularly catheter ablation, can improve AF outcomes.
- Optimizing the timing, use, and efficacy of interventions may reduce the long-term mortality associated with AF.
- New evidence provides optimism for improving the natural history of atrial fibrillation.
Abstract:
Atrial fibrillation (AF) is significantly associated with morbidity and mortality and erodes the quality and quantity of life. It is standard of care to treat patients with AF and an increased risk of stroke with oral anticoagulation therapy, but the more daunting question many clinicians face is whether to pursue a "rate-only" or "rhythm" control strategy. Historical studies over the years have sought to answer this question but have found no significant difference in major clinical outcomes between the two strategies. There are opportunities based on new data to improve the natural history of the disease. The EAST AFnet trial for the first time revealed a significant morbidity and mortality advantage to rhythm control therapy when performed early in the disease process of AF and in the setting of comprehensive medical management that was maintained. The CABANA trial clearly demonstrated that catheter ablation was a more effective long-term treatment of AF in general and significantly lowers risk of AF progression compared to medical therapy. Like multiple prior trials of rhythm management strategies, when rhythm control was effective in these trials, independent of therapy assignment, there was a significantly lower risk of adverse outcomes and death. These contemporary data provide optimism that the pervasive mortality risk in patients with AF observed over the past 50 years may be improved by the timing, use, and efficacy of use of therapeutic interventions.
